Helix BioPharma (TSE:HBP) Sets New 52-Week High - Here's Why

Key Points

• Helix BioPharma Corp. shares reached a new 52-week high of C$1.52 during trading, up from a previous close of C$1.51.
• The company, with a market capitalization of C$116.09 million, focuses on cancer drug development using proprietary technology in the field of immuno-oncology.
• Helix BioPharma's stock has a price-to-earnings ratio of -1.48, indicating it is currently operating at a loss.

Shares of Helix BioPharma Corp. (TSE:HBP - ) hit a new 52-week high during mid-day trading on Monday . The company traded as high as C$1.52 and last traded at C$1.52, with a volume of 115 shares. The stock had previously closed at C$1.51.

Helix BioPharma Stock Up 0.7%

The business has a 50-day simple moving average of C$1.20 and a two-hundred day simple moving average of C$0.99. The stock has a market capitalization of C$116.09 million, a price-to-earnings ratio of -1.48 and a beta of -0.45.

About Helix BioPharma

Helix BioPharma Corp is a clinical-stage biopharmaceutical company. It is focused on cancer drug development. The company develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. Its pipeline candidates are Tumor Defence Breaker L-DOS47, and, V-DOS47 among others.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.